Angiotensin converting enzyme (ACE) inhibitors have been shown to improve survival and to
reduce the risk of cardiovascular events in some groups of patients following myocardial
infarction. This study is designed to test whether early initiation (≤7 days) of an ACE
inhibitor post-coronary artery bypass graft (CABG), would reduce cardiovascular events. The
trial was a double-blind, placebo controlled study of 2,553 patients randomly assigned to
quinapril, target dose 40 mg daily or placebo, followed up to 43 months.
Angiotensin converting enzyme (ACE) inhibitors have been shown to improve survival and to
reduce the risk of cardiovascular events in some groups of patients following myocardial
infarction. This study is designed to test whether early initiation (≤7 days) of an ACE
inhibitor post-coronary artery bypass graft (CABG), would reduce cardiovascular events. The
trial was a double-blind, placebo controlled study of 2,553 patients randomly assigned to
quinapril, target dose 40 mg daily or placebo, followed up to 43 months.
Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF
Completed
Nova Scotia Health Research Foundation
Phase 4
2009-12-01
Atrial fibrillation (AF) is a very common arrhythmia causing many symptoms resulting in
numerous hospitalizations. Catheter ablation is a technique that has evolved significantly to
improve symptomatic recurrences, but does not offer a 100% cure rate. We hypothesize that the
use of aggressive BP lowering will reduce the rate of recurrent AF after catheter ablation
for AF. We plan a randomized clinical trial of aggressive BP lowering versus standard BP
control to investigate this.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
